Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sintilimab - Eli Lilly and Company/Innovent Biologics

Drug Profile

Sintilimab - Eli Lilly and Company/Innovent Biologics

Alternative Names: IBI-308; PD-1 antibody - Eli Lilly and Company/Innovent Biologics; Sintilimab injection - Eli Lilly and Company/Innovent Biologics; Tyvyt

Latest Information Update: 20 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adimab; Innovent Biologics
  • Developer Innovent Biologics; Jiangsu Provincial Peoples Hospital; Peking University; Shanghai Jiaotong University School of Medicine; Sun Yat-Sen University; Tianjin Medical University Cancer Institute and Hospital
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hodgkin's disease
  • Phase III Gastric cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer
  • Phase II/III Liver cancer
  • Phase II Extranodal NK-T-cell lymphoma; Small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 12 Jan 2020 Innovent and Eli Lilly intends to initiate a regulatory discussions for registration with the National Medical Products Administration (NMPA) in China
  • 12 Jan 2020 Interim efficacy data from a phase III ORIENT-11 trial in Non small cell lung cancer released by Innovent Biologics
  • 07 Jan 2020 Innovent and Sirnaomics enter into a strategic collaboration for a clinical trial for Hepatocellular carcinoma and cholangiocarcinoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top